FACIT is a commercialization venture firm that builds companies with entrepreneurs to accelerate oncology innovation, with a portfolio that has attracted over $850 million in investment to Ontario. Blending industry experience, capital and the unsurpassed clinician-scientist network of its strategic partner the Ontario Institute for Cancer Research (OICR), FACIT capitalizes on the province’s investment in research and healthcare to the benefit of the local economy and patients worldwide. FACIT’s commercialization portfolio includes Turnstone Biologics, Fusion Pharmaceuticals, Triphase Accelerator and other biotechnology organizations. Cancer Breakthroughs. Realized. facit.ca.



Contact Information
Connie Chen, PhD
Senior Director, Strategy & Corporate Development
Tel: 647-260-7934
[email protected]

Latest

May 04, 2015, 09:00 ET Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline

TORONTO, May 4, 2015 /CNW/ - Fluorinov Pharma (Fluorinov), a FACIT portfolio company, is pleased to announce the appointment of Dr. Roger J Garceau, to its Board of Directors. With extensive...

May 04, 2015, 08:30 ET Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies

FACIT partners with Ontario researchers to create new company TORONTO, May 4, 2015 /CNW/ - The Fight Against Cancer Innovation Trust (FACIT) and its partners are pleased to announce the formation of...

Jan 07, 2015, 12:08 ET Fluorinov Pharma and FACIT Announce Investment in Breakthrough Bromodomain Inhibitors for the Treatment of Cancers

TORONTO, Jan. 7, 2015 /CNW/ - FACIT and Fluorinov Pharma announced today an investment in the development of highly potent inhibitors of key bromodomain targets. Targeting drugs to epigenetic...

Apr 24, 2014, 14:34 ET Fluorinov Pharma, FACIT and OICR announce novel candidate drugs modulating NaV 1.8, NaV 1.7 sodium channels for the safer treatment of cancer pain and brain cancer-related epilepsy

TORONTO, April 24, 2014 /CNW/ - Fluorinov Pharma, an emerging Ontario-based drug development company, has developed three structurally distinct candidate drugs that selectively target pain-specific...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE